Concepedia

Author

Stefan Bourgeois

Ziekenhuisnetwerk Antwerpen Stuivenberg

Also Known As

BOURGEOIS S, Christophe Claessens, Håvard Midgard, S Bourgeois, S. Bourgeois, Stefan A. Bourgeois, Stefan Bourgeois

90

Publications

1.2K

Citations

15

H-Index

40

Concepts

All Affiliations

Ziekenhuisnetwerk Antwerpen StuivenbergErasmus HospitalAntwerp University HospitalZiekenhuis Oost-LimburgGhent University Hospital
SB

About

Stefan Bourgeois is an author at Ziekenhuisnetwerk Antwerpen Stuivenberg specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

470

2

Hepatology

3

3

93

3

Health Sciences

1

1

39

4

Public Health

1

1

39

5

Gastroenterology

1

1

10

Stefan Bourgeois

×

26

Publications

1.1K

Citations

14

H-Index

YearCitations

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks

Jordan J. Feld, Christophe Moreno, Roger Trinh,

Journal of Hepatology

2015

160

Efficacy of the Long-Acting Repeatable Formulation of the Somatostatin Analogue Octreotide in Postoperative Dumping

Joris Arts, Philip Caenepeel, Raf Bisschops,

Clinical Gastroenterology and Hepatology

2008

138

JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection

Fabien Zoulim, Oliver Lenz, Joris Vandenbossche,

Gastroenterology

2020

114

Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4

Christophe Moreno, Christophe Hézode, Patrick Marcellin,

Journal of Hepatology

2015

81

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

Man‐Fung Yuen, Tarik Asselah, Ira M. Jacobson,

˜The œLancet. Gastroenterology & hepatology

2023

64

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

Harry L.A. Janssen, Jinlin Hou, Tarik Asselah,

Gut

2023

53

Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis

Tarik Asselah, Stefan Bourgeois, Stephen Pianko,

Liver International

2017

51

Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after <scp>HB</scp> eAg seroconversion is associated with high relapse rates and fatal outcomes

Stijn Van Hees, Stefan Bourgeois, Hans Van Vlierberghe,

Alimentary Pharmacology & Therapeutics

2018

50

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C‐infected patients treated with direct‐acting antivirals with and without pegylated interferon: A Belgian experience

Rob Bielen, Christophe Moreno, Hans Van Vlierberghe,

Journal of Viral Hepatitis

2017

44

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study

Håvard Midgard, Behzad Hajarizadeh, Evan B. Cunningham,

International Journal of Drug Policy

2017

39

Page 1